HUMALOG MIX 75/25 KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMALOG MIX 75/25 KWIKPEN (HUMALOG MIX 75/25 KWIKPEN).
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
| Metabolism | Insulin lispro is metabolized by proteolytic cleavage, primarily via insulin-degrading enzyme (IDE) in the liver and kidneys. |
| Excretion | Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible. |
| Half-life | 4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia. |
| Protein binding | <10% bound to plasma proteins (primarily albumin); minimal binding, with clinical significance only in extreme conditions. |
| Volume of Distribution | Approximately 0.3 L/kg (reflecting distribution primarily into extracellular fluid; this is less than regular insulin due to rapid clearance). |
| Bioavailability | Subcutaneous: 55-75% (variable, dependent on injection site, depth, and technique; the formulation is a pre-mixed suspension of 75% insulin lispro protamine suspension and 25% insulin lispro solution). |
| Onset of Action | Subcutaneous: 15-30 minutes. |
| Duration of Action | Subcutaneous: 2-4 hours for glucose-lowering effect (shorter than regular insulin, with a peak at 0.5-2.5 hours). |
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment for this combination insulin product. Monitor glucose closely in renal impairment due to increased risk of hypoglycemia. Initiate with lower doses in GFR <30 mL/min. |
| Liver impairment | No specific Child-Pugh based adjustment. Monitor glucose closely in hepatic impairment due to altered glucose metabolism and increased hypoglycemia risk. Start with cautious dosing. |
| Pediatric use | Weight-based: 0.5-1.0 units/kg/day subcutaneously, divided into preprandial doses. Not recommended for children <12 years due to lack of data. |
| Geriatric use | Initiate at lower doses (e.g., 10-20% less than usual adult dose) due to increased risk of hypoglycemia. Titrate based on glucose targets and comorbidities. Monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMALOG MIX 75/25 KWIKPEN (HUMALOG MIX 75/25 KWIKPEN).
| Breastfeeding | Insulin lispro is a large protein molecule that is minimally excreted into breast milk. The M/P ratio is not established, but oral bioavailability is negligible due to digestion in the infant's gastrointestinal tract. It is considered compatible with breastfeeding. Caution is advised to monitor maternal glucose levels to avoid hypoglycemia. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. No teratogenic effects have been observed in animal studies. During the first trimester, poor glycemic control increases the risk of spontaneous abortion and congenital anomalies. In the second and third trimesters, maternal hyperglycemia can lead to fetal macrosomia, neonatal hypoglycemia, and respiratory distress syndrome. Insulin lispro is considered low risk for fetal harm when used to maintain glycemic control. |
■ FDA Black Box Warning
Never share a Humalog KwikPen between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
["Hypoglycemia","Hypersensitivity to insulin lispro or any excipients"]
| Precautions | ["Risk of hypoglycemia","Changes in insulin regimen may affect glycemic control and precipitate hypoglycemia or hyperglycemia","Hypersensitivity and allergic reactions","Medication errors: inadvertent mix-ups between insulin products","Hypokalemia: insulin therapy can cause hypokalemia"] |
Loading safety data…
| Fetal Monitoring | Monitor blood glucose levels frequently (before and after meals, at bedtime) to achieve tight glycemic control. Monitor HbA1c every 1-2 months. Assess fetal growth via ultrasound (e.g., for macrosomia) in the third trimester. Perform fetal non-stress tests or biophysical profiles as indicated for high-risk pregnancies. |
| Fertility Effects | Human insulin products are not associated with adverse effects on fertility. Adequate glycemic control is important for normal menstrual cycles and fertility. No specific data on insulin lispro affecting human fertility; animal studies showed no impairment. |